Author

Graydon Harker

Observed names: G Harker, G. Harker, Harker, Graydon

Observed institutions: Boston University, BC Cancer Agency, Guy's Hospital, University of Miami, University of New Mexico, King's College London, Guy's and St Thomas' NHS Foundation Trust, Curtin University, Texas Oncology, Auckland City Hospital, Asan Medical Center, Institut Gustave Roussy, Rigshospitalet, Yale Cancer Center, Hospital General Universitario Gregorio Marañón, St. Elizabeth's Medical Center, Massachusetts General Hospital, Utah Cancer Specialists, Osaka National Hospital, Comprehensive Cancer Center Vienna, Compass Oncology, International Drug Development Institute (Belgium), Institut za onkologiju i radiologiju Srbije, Virginia Cancer Specialists, Sisters of Charity Hospital, German Breast Group, Aichi Cancer Center, Lillebaelt Hospital, Puma Biotechnology (United States), International Drug Development, UNM Comprehensive Cancer Center, Aichi Cancer Center Hospital, Pontifícia Universidade Católica do Rio Grande do Sul, Medical University of Vienna

OpenAlex ID: A5050943019

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

1997 · P J Hesketh, M G Kris, et al. · Journal of Clinical Oncology · 605

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

1991 · J Hainsworth, W Harvey, et al. · Journal of Clinical Oncology · 154

The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

2009 · A. Brufsky, G. Harker, et al. · Cancer Research · 59

Prognostic Indicators in Head and Neck Cancer Patients Receiving Combined Therapy

1989 · R. K. Davis, K. Stoker, et al. · Archives of Otolaryngology - Head and Neck Surgery · 23

Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A southwest oncology group study

1987 · R B Livingston, S Schulman, et al. · Lung Cancer · 16

Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer

2006 · M. R. Moore, C. Jones, et al. · Journal of Clinical Oncology · 14

Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

2016 · A Chan, S Delaloge, et al. · Cancer Research · 13

Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04–012)

2008 · B. Mirtsching, T. Cosgriff, et al. · Journal of Clinical Oncology · 4

Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST).

2009 · A Brufsky, G Harker, et al. · Cancer Research · 3

Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial

2018 · SKL Chia, M Martin, et al. · Cancer Research · 1

Works count: 13

Citation count: 892

H-index: 7

I10-index: 7